The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Momenta Pharmaceuticals Inc

Nasdaq: MNTA
Last

(U.S.) $16.60

Today's change-0.15 -0.90%
Updated July 27 11:11 AM EDT. Delayed by at least 15 minutes.
 

Momenta Pharmaceuticals Inc

Nasdaq: MNTA
Last

(U.S.) $16.60

Today's change-0.15 -0.90%
Updated July 27 11:11 AM EDT. Delayed by at least 15 minutes.

Momenta Pharmaceuticals Inc down (U.S.)$0.15

Momenta Pharmaceuticals Inc is lower today, dropping (U.S.)$0.15 or 0.90% to (U.S.)$16.60. Shares have lost 3.77% over the last five days, but have gained 10.30% over the last year to date. This security has outperformed the S&P 500 by 27.20% during the last year.

Key company metrics

  • Open(U.S.) $16.75
  • Previous close(U.S.) $16.75
  • High(U.S.) $16.75
  • Low(U.S.) $16.50
  • Bid / Ask(U.S.) $16.65 / (U.S.) $16.70
  • YTD % change+10.30%
  • Volume60,899
  • Average volume (10-day)387,999
  • Average volume (1-month)634,492
  • Average volume (3-month)744,846
  • 52-week range(U.S.) $10.50 to (U.S.) $19.90
  • Beta1.81
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$0.41
Updated July 27 11:11 AM EDT. Delayed by at least 15 minutes.
S&P TSX0.30%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q1/2017Q4/2016Q3/2016Q2/2016
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedMar 31, 201703/31/2017Dec 31, 201612/31/2016Sep 30, 201609/30/2016Jun 30, 201606/30/2016
Revenue27342926
Total other revenue--------
Total revenue27342926
Gross profit--------
Total cost of revenue--------
Total operating expense59454748
Selling / general / administrative23181615
Research & development36263233
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total--------
Operating income-33-10-18-22
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax-3242-18-21
Income after tax-3242-18-21
Income tax, total--------
Net income-3242-18-21
Total adjustments to net income--------
Net income before extra. items-3242-18-21
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-3242-18-21
Inc. avail. to common incl. extra. items-3242-18-21
Diluted net income-3242-18-21
Dilution adjustment--------
Diluted weighted average shares70696969
Diluted EPS excluding extraordinary itemsvalue per share-0.460.60-0.26-0.31
Dividends per sharevalue per share0.000.00--0.00
Diluted normalized EPSvalue per share-0.460.60-0.26-0.31